Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study

• Published in: Journal of Korean medical science Vol. 29; no. 1; pp. 90 - 97
• Main Authors: Lee, Mi Young, Choi, Dong Seop, Lee, Moon Kyu, Lee, Hyoung Woo, Park, Tae Sun, Kim, Doo Man, Chung, Choon Hee, Kim, Duk Kyu, Kim, In Joo, Jang, Hak Chul, Park, Yong Soo, Kwon, Hyuk Sang, Lee, Seung Hun, Shin, Hee Kang
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Academy of Medical Sciences 01.01.2014; 대한의학회
• Subjects: Acarbose - adverse effects; Acarbose - therapeutic use; Blood Glucose; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - therapeutic use; Female; Glycated Hemoglobin - analysis; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Inositol - adverse effects; Inositol - analogs & derivatives; Inositol - therapeutic use; Insulin - blood; Insulin - therapeutic use; Male; Metformin - therapeutic use; Middle Aged; Original; Prospective Studies; 의학일반; Voglibose; Acarbose; Diabetes Mellitus, Type 2
• ISSN: 1011-8934; 1598-6357; 1598-6357
• DOI: 10.3346/jkms.2014.29.1.90

We studied the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetes patients whose blood glucose levels were inadequately controlled with basal insulin alone or in combination with metformin (or a sulfonylurea). This study was a 24-week prospective, open-label, randomized, active-controlled multi-center study. Participants were randomized to receive either acarbose (n=59, 300 mg/day) or voglibose (n=62, 0.9 mg/day). The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose (from 8.43% ± 0.71% to 7.71% ± 0.93%) and voglibose groups (from 8.38% ± 0.73% to 7.68% ± 0.94%). The mean fasting plasma glucose level and self-monitoring of blood glucose data from 1 hr before and after each meal were significantly decreased at week 24 in comparison to baseline in both groups. The levels 1 hr after dinner at week 24 were significantly decreased in the acarbose group (from 233.54 ± 69.38 to 176.80 ± 46.63 mg/dL) compared with the voglibose group (from 224.18 ± 70.07 to 193.01 ± 55.39 mg/dL). In conclusion, both acarbose and voglibose are efficacious and safe in patients with type 2 diabetes who are inadequately controlled with basal insulin. (ClinicalTrials.gov number, NCT00970528).